Experts explore how leukapheresis is emerging as a critical chokepoint for both autologous and allogeneic cell therapies. The post CGT’s next obstacle: Securing the leukapheresis supply chain appeared first on Clinical Trials Arena .
CGT’s next obstacle: Securing the leukapheresis supply chain